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The risk of venous thromboembolism after hysterectomy for benign disease is generally low, 42 
highest with an abdominal procedure, and particularly low after laparoscopic and vaginal 43 
procedures.  44 
 45 
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Study Objective: To estimate the risk of venous thromboembolic complications following 47 
abdominal, laparoscopic and vaginal hysterectomy when performed for benign disorders.  48 
Design: Nationwide cohort study (Canadian Task Force Classification II-2).  49 
Setting: Data from Danish national registers on all women undergoing hysterectomy for benign 50 
conditions in the period 1996-2015. 51 
Patients: Women aged 18 and above who underwent hysterectomy for benign disease were 52 
stratified into 3 groups according to hysterectomy approach: abdominal, laparoscopic or vaginal. 53 
Intervention: Hysterectomy. 54 
Measurements and Main Results: 89,931 women met the inclusion criteria. Venous 55 
thromboembolism (VTE) as a diagnosis or cause of death was identified. Risk of postoperative 56 
VTE was examined with Cox proportional hazard models adjusting for age, surgical approach and 57 
relevant comorbidities. Mean age was 49.9, 47.9 and 54.3 years for women with abdominal, 58 
laparoscopic and vaginal hysterectomy, respectively. Crude incidences of VTE within 30 days after 59 
hysterectomy were 0.24% (n=142), 0.13% (n=12) and 0.10% (n=21).  The most important 60 
predictors of VTE were approach to hysterectomy and a history of thromboembolic disease. In the 61 
multivariable analysis risk of VTE was significantly reduced with laparoscopic hysterectomy (HR 62 
0.51; 95% CI 0.28-0.92, P=.03) and vaginal hysterectomy (HR 0.39; 95% CI 0.24-0.63, P<.001) 63 
when compared to the abdominal procedure. Data on postoperative heparin thromboprophylaxis 64 
were available in 53,566 patients and adjusted HR was 0.63 (95 % CI 0.42-0.96, P=.03) in patients 65 
receiving heparin thromboprophylaxis.  66 
Conclusions: The 30-day cumulative incidence of VTE after hysterectomy for benign conditions 67 
was low overall (0.19%).  Laparoscopic and vaginal hysterectomy carry a lower risk than the 68 
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abdominal procedure. Postoperative heparin thromboprophylaxis significantly reduces risk of VTE 69 
and should be considered especially if risk factors are present.   70 
 71 
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Postoperative venous thromboembolism (VTE) is the second-most common medical complication 97 
to general surgery and results in excess morbidity and mortality[1]. The most feared consequence, 98 
pulmonary embolism (PE), is the most common preventable cause of hospital death[1]. Deep vein 99 
thrombosis (DVT) and PE are preventable with proper thromboprophylaxis as demonstrated in 100 
clinical trials[2]. 101 
One of the most common gynecologic procedures is hysterectomy with 400- 600,000 procedures 102 
per year in the United States[3,4]. Few studies have focused on the incidence of VTE in women 103 
undergoing hysterectomy for benign conditions. There are three different approaches to 104 
hysterectomy: abdominal, laparoscopic and vaginal. In 2015, 20 % were performed as abdominal, 105 
64 % as laparoscopic assisted (including robotic-assisted surgery) and 16 % as vaginal 106 
hysterectomies in Denmark[5]. The risk of postoperative DVT and PE, in patients undergoing 107 
surgery for benign conditions, is presumed to be low in general[6,7], and in particular when 108 
performed laparoscopically[8]. This is probably the reason, why pharmacologic VTE prophylaxis 109 
has not been used systematically. Despite being the recommendation in most clinical guidelines, 110 
the proportion of patients actually receiving thromboprophylaxis after hysterectomy may be as low 111 
as 11.9%[6]. Danish guidelines recommend postoperative venous thromboprophylaxis with low 112 
molecular weight heparin administered 4-12 hours following hysterectomy in prophylactic dose 113 
once daily until discharge from hospital, this can optionally be supplemented with graduated elastic 114 
compression stockings[9]. Few studies have focused on VTE in benign gynecologic surgery and 115 
recommendations on thromboprophylaxis have mostly been based on the experience from 116 
abdominal surgery and study populations with a broad variation of risk factors[10]. The striking 117 
difference between clinical practice and guidelines calls for a more precise estimation of risk of 118 
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Materials and Methods 123 
Data-sources 124 
This study is based on data from national Danish administrative registries.  125 
In Denmark, every resident is at the time of birth or immigration assigned a unique and permanent 126 
civil registration number, which enables linkage between nationwide administrative registers on the 127 
individual level. The Danish National Patient Register (DNPR) was established in 1977 and holds 128 
data on all hospitalizations in Denmark[11]. Each admission is registered at discharge with one 129 
primary and if appropriate one or more secondary diagnoses according to the International 130 
Classification of Diseases, the 10th revision (ICD-10). Surgical procedures are registered according 131 
to the Nordic Medico-statistical Committee’s Classification of Surgical Procedures[12], together 132 
with the indication for the procedure. There could be multiple indications for hysterectomy. 133 
We retrieved information on hormone substitution and anticoagulant treatment from The Danish 134 
Register of Medicinal Product Statistics where all prescription based pharmacy dispensings are 135 
stored. The National Population Register and the National Causes of Death Register hold 136 
information on vital status, date of birth and death including cause of death.  137 
Study population 138 
All patients who underwent hysterectomy from January 1st 1996 until December 31st 2015 were 139 
identified. The patients were separated into three groups according to the surgical approach: 140 
abdominal (subtotal or total abdominal hysterectomy comprised the codes KLCD00, KLCD96, 141 
KLCC10), laparoscopic (total, subtotal, vaginal and robotic assisted laparoscopic hysterectomy 142 
comprised the codes KLCD01, KLCD04, KLCC11, KLCD11, KLCD97) or vaginal (total or subtotal 143 
comprised the codes KLCD10, KLCC20, colpoperineoplasty and vaginal hysterectomy KLEF13).  144 
Patients diagnosed with any type of cancer within 1 month prior to surgery or two months following 145 
the surgical procedure were excluded (ICD10 codes DC00-96). Radical hysterectomies (KLCD30, 146 
KLCD31, KLCD40) were excluded because these procedures are only performed in the case of 147 
gynecologic malignancy. We did not include hysterectomies performed at the same time as 148 
cesarean section or hysterectomy performed at the same time as cystectomy in the case of urine 149 
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bladder malignancy. 150 
Patients were excluded if the specific date of surgery was not defined.  151 
Outcome 152 
VTE comprised the following ICD-10 codes: I80.1 (phlebitis or thrombophlebitis in the femoral 153 
vein), I80.2 (deep phlebitis or thrombophlebitis in other veins in lower extremities), I80.3 (deep 154 
phlebitis or thrombophlebitis in other veins in lower extremities without specification), I80.8 155 
(phlebitis or thrombophlebitis at other locations), I80.9 (phlebitis or thrombophlebitis without 156 
specification) and I26 (pulmonary embolism). If one of these codes occurred prior to the date of 157 
hysterectomy it was registered as a previous VTE. If the code was assigned to a patient within one 158 
month after hysterectomy it was registered as a postoperative VTE. 159 
Confounders 160 
Use of hormones or antithrombotic agents prior to surgery was defined as at least one claimed 161 
prescription within 180 days before surgery of the following agents: oral contraceptives with 162 
estrogen in combination with progesterone (Anatomical Therapeutic Chemical Classification G03A, 163 
G03HB01) or hormone therapy (estrogen as monotherapy or in combination with progesterone, 164 
both orally and transdermal administrated G03F, G03CX, G03CA and G03CB; low dose estrogen 165 
vagitories were excluded by product number). Antithrombotic agents were defined including 166 
antiplatelet drugs (B01AC) and anticoagulant drugs (B01 except B01AC).  167 
Co-morbidities were defined as one of the following ICD-10 codes if the code was used at 168 
discharge within 365 days prior to the hysterectomy date: ischemic heart disease (I20, I23, I24, 169 
I25), cerebral vascular disease (I60-69), acute myocardial infarction (I21), varices of the lower 170 
extremities (I83), thrombophilia (D68), heart failure ((I50), chronic obstructive lung disease (J44). 171 
Two time periods were compared as the Danish Board of Health in 2003 published a national 172 
guideline for benign hysterectomy including recommendations on postoperative VTE prophylaxis 173 
with heparin injections and graduated elastic compression stockings during hospitalization[13]. A 174 
Danish national hysterectomy database was established in October 2003 and one of the clinical 175 
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indicators is the use of VTE prophylaxis which is registered in the DNPR by the clinicians 176 
(BOHA03C). 177 
Information on Body Mass Index (BMI) was obtained from the Danish Anesthesia Database (DAD). 178 
This information was not available for all patients since the database was established in 2004 and 179 
it does not cover all departments in Denmark. 180 
Data are reported in accordance with the STROBE statement[14]. 181 
 182 
Statistics 183 
Cumulative incidence was calculated for the competing risks VTE and death after abdominal, 184 
laparoscopic and vaginal hysterectomy respectively. Time to event was calculated from the date of 185 
surgery, follow-up time was 30 days and data were analyzed using univariable and multivariable 186 
Cox proportional hazard regression. Hazard ratios (HRs) of VTE after abdominal, laparoscopic and 187 
vaginal hysterectomy were hence estimated and presented with 95% confidence intervals (95% 188 
CI). A P-value less than 0.05 was considered statistically significant. Plots of Schoenfeld Residuals 189 
were used to examine the proportional hazard assumption. Linearity between the continuous 190 
variable age and outcome was tested. Interaction between approach to hysterectomy and 191 
presence of uterine fibroids was tested using analysis of variance. 192 
Calculations were performed using SAS V.9.4 (SAS Institute, Cary, North Carolina, USA) and R 193 
version 3.1.0 (R Core Team (2014))[15].  194 
 195 
Ethics  196 
The study was approved by The Danish Data Protection Agency (Re: 2007-58-0015, int.ref: GEH-197 
2010-001). Permission from the ethics committee is not required for retrospective register studies 198 
in Denmark. 199 
 200 
Results 201 
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We identified 89,931 patients who underwent hysterectomy for benign conditions in the period 202 
January 1st 1996 until December 31st 2015. Patients were divided into three groups according to 203 
the route of hysterectomy: Abdominal (n=59,231), laparoscopic (n=9,198) and vaginal (n=21,502) 204 
(figure 1). Table 1 shows the demographic data of the cohort according to age at surgery, length of 205 
stay, body mass index (BMI), concomitant disease, use of medicine before surgery, the indication 206 
for hysterectomy and postoperative pharmacologic VTE prophylaxis. Women undergoing vaginal 207 
hysterectomy were older and more likely to have comorbidities, although the general incidence of 208 
comorbidity was low in the total cohort. The indication for hysterectomy was uterine prolapse in 209 
more than 50 % of cases within the vaginal hysterectomy group. In the abdominal and 210 
laparoscopic hysterectomy groups, uterine fibroids and abnormal uterine bleeding were the 211 
dominant causes.  212 
Comparing the two time periods before and after January 1st, 2004 showed that the proportion of 213 
minimally invasive hysterectomy was increasing during the study period with 29,060 abdominal 214 
approaches in 36,365 hysterectomies before 2004 ~80 %. After January 1st, 2004 44 % of 215 
hysterectomies were performed as laparoscopic and vaginal procedures.  216 
During 30-day follow up after surgery we observed 175 cases of VTE with 100 cases of PE. There 217 
were 109 deaths in the abdominal hysterectomy group compared to one in the laparoscopic and 218 
12 in the vaginal hysterectomy group. 219 
Competing risk analysis of the cumulative incidence of VTE showed higher incidence with open 220 
surgery compared to the two minimally invasive methods. Cumulative incidence of mortality 221 
showed the highest incidence with open surgery compared to the two minimally invasive methods. 222 
(Figures S1 and S2 are provided in supplemental material).  223 
Unadjusted HRs in different exposure groups are provided in table 2. The indication for 224 
hysterectomy could be strongly correlated to the choice of surgery approach as surgeons might 225 
prefer to perform abdominal hysterectomy in the presence of uterine and ovarian neoplasms. 226 
Statistical testing showed no evidence of interaction between hysterectomy approach and uterine 227 
fibroids (P=0.35). 228 
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Length of stay was associated with surgical approach (table 1) with median value highest in the 229 
abdominal hysterectomy group and univariable analysis (table 2) shows that it is significantly 230 
associated with HR of VTE. 231 
Adjusting for age, time period, ovarian and uterine neoplasms, relevant drugs and concomitant 232 
disease, the laparoscopic (HR 0.51; 95% CI 0.28-0.92, P=.03) and vaginal (HR 0.39; 95% CI 0.24-233 
0.63, P<.001) procedures are correlated with a significantly reduced HR of VTE when compared to 234 
abdominal hysterectomy (figure 2).  235 
The use of oral hormonal contraceptives or hormone therapy did not influence on the HR of VTE in 236 
women undergoing hysterectomy (figure 2 and 3). In contrast, anticoagulant drugs, previous acute 237 
myocardial infarction (AMI) and previous VTE significantly increase the HR of VTE (figure 2 and 3). 238 
Usage of postoperative heparin as VTE prophylaxis has been registered in the DNPR since 2004. 239 
There is no change in the impact of the different factors included in the first model (figure 2) when 240 
performing the same multivariable analysis on hysterectomies performed after 2003 including VTE 241 
prophylaxis instead of time period (figure 3). This subgroup analysis shows a reduced HR (0.63; 242 
95% CI 0.42-0.96, P=.03) for VTE in patients receiving pharmacologic VTE prophylaxis.  243 
Data on BMI were available in 11,177 patients with overall mean BMI 26.1 (SD 5.0) and 19 VTE 244 
events (table 1). We found no difference in risk of VTE between BMI groups in a univariable Cox 245 
proportional hazard regression analysis. Because of the smaller number of events we did not 246 
attempt of multivariable analysis including BMI.  247 
 248 
Discussion 249 
This study demonstrates that the 30-day incidence of postoperative VTE after hysterectomy for 250 
any benign condition is low. The rate of VTE was lowest in patients treated with laparoscopic and 251 
vaginal hysterectomy compared to the abdominal approach.   252 
 A Cochrane review (2009) comparing the complication rates between different procedures 253 
concluded that vaginal hysterectomy was superior to abdominal on almost all outcome measures 254 
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and recommended laparoscopic surgery in cases where vaginal hysterectomy could not be 255 
performed[17]. However, there was no apparent difference in the VTE incidence according to 256 
surgical approach, probably due to limited power.  257 
Barber et al (2014) found an overall incidence of VTE at 0.35 % in 44,167 women undergoing 258 
hysterectomy for benign conditions and showed abdominal hysterectomy to be associated with 259 
higher risk of VTE compared to minimally invasive surgery (OR 2.45; CI 1.77-3.40)[18]. Swenson 260 
et al (2015) registered 110 VTE events (0.5%) during 30 days of follow-up in 20,496 women with 261 
hysterectomy for benign, malignant and obstetric indications. Prominent risk factors were 262 
abdominal approach, cancer, BMI>35 and increased surgical time[19]. 263 
The frequency of VTE in these studies is consistent with our findings. The association between 264 
BMI and VTE is debated and experience from bariatric surgery suggests that it has been 265 
overestimated[20]. We found no association between BMI and VTE in a subgroup of the cohort; 266 
due to missing data, we could not include BMI in the multivariable analysis. 267 
White et al (2003) showed, that the incidence of first-time VTE increases exponentially with age 268 
with a dramatically increase after the age of 60[21]. Ritch et al (2011) identified age as a significant 269 
risk factor of VTE after hysterectomy[6].  270 
In accordance with these studies we found the crude HR of VTE increasing with age in the 271 
unadjusted model. This association could not be reproduced in the multivariable models, indicating 272 
a stronger association between VTE and approach to hysterectomy.  273 
Several studies have reported an increased risk of VTE with hormone therapy (HT) [22]. In the 274 
present study we found no difference in HR between women on HT or oral contraceptives 275 
containing estrogen compared to women not exposed. 276 
A benign pelvic mass might compress the iliac veins leading to venous stasis and subsequent 277 
thrombosis. Fletcher et al. (2009) found an increased risk of VTE (OR 3.75; CI 2.92-4.78, P<.001) 278 
among women with uterine fibroids with and without surgery when compared to the expected rate 279 
in hospitalized women[23]. Shiota et al. (2011) found an overall incidence of preoperative 280 
asymptomatic DVT at 3.7 % (31/843) in patients with benign ovarian tumors[24]. Our analysis 281 
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indicated no correlation between any benign indication for hysterectomy and risk of postoperative 282 
symptomatic VTE. Our dataset did not contain neoplastic size, therefore, the possible impact of 283 
large tumors on VTE risk cannot be assessed.  284 
It must be emphasized that we can only report cases of symptomatic VTE´s. The incidence would 285 
probably be higher with more sensitive methods as demonstrated in randomized controlled 286 
trials[2].  287 
In Denmark, thromboprophylaxis is administered by the hospital and was not registered in the 288 
DNPR before 2004. Hansen et al. (2008) reported an increase in heparin thromboprophylaxis 289 
administered following hysterectomy from 20 % in 2004 to more than 90 % of patients undergoing 290 
hysterectomy for benign disease in 2006[25]. Surgeons were probably paying more attention to 291 
VTE prophylaxis after the establishment of the Danish Hysterectomy and Hysteroscopy Database 292 
and implementation of recommendations on postoperative VTE prophylaxis. Our results indicate a 293 
significant reduction in risk of VTE following hysterectomy for benign conditions when 294 
pharmacologic VTE prophylaxis was administered during hospital stay after surgery. The ACOG  295 
Practice Bulletin (2007) recommends initiation of venous thromboprophylaxis with graduated 296 
compression stockings or pneumatic compression devices before surgery as VTE begins in the 297 
perioperative period[10]. Our results show a decrease in HR of VTE in patients receiving 298 
postoperative heparin which is supported by Hansen et al. (2008) who found preoperative 299 
administration associated with higher risk of bleeding complications compared to postoperative 300 
administration and no apparent difference in risk of VTE.[26] From our study we cannot draw any 301 
conclusions on the timing of VTE prophylaxis. Not all patients received prophylaxis, it is likely that 302 
patients within a fast track regimen undergoing MIS are discharged before heparin administration.  303 
Increasing length of stay increased the HR of VTE in a univariable analysis (table 2), despite this 304 
finding we did not include it in the multivariable analysis as we believe the variable is not a 305 
confounder because it is on the causal pathway between main exposure and outcome[27]. Talec 306 
et al (2016) suggest individual evaluation of thromboprophylaxis in each patient based on patient-307 
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related risk factors, type of surgery including length of operation and duration to mobilization[28]. 308 
Our results support this approach to the planning of VTE prophylaxis. 309 
The strength of epidemiologic research using national registries is the availability of a large patient 310 
cohort. Through our study, we found an important association between the risk of VTE and the 311 
approaches to hysterectomy. Groups were considered highly comparable according to baseline 312 
characteristics. The vaginal approach was used more often in case of pelvic organ prolapse and 313 
the abdominal approach in the presence of benign neoplasms, consistent with available 314 
gynecologic guidelines[29,30]. Bias could arise from misclassification of diseases and treatments. 315 
We calculated cumulative incidence of VTE considering mortality as a competing risk to illustrate 316 
how mortality affect the probability of a VTE event to occur. As mortality was highest in the 317 
abdominal hysterectomy group we found no reason to think mortality precluded the occurrence of 318 
VTE in the laparoscopic and vaginal hysterectomy groups. 319 
The coding of co-morbidity and coexisting diseases in DNPR is validated by Thygesen et al. 320 
(2011), with a positive predictive value ranging from 82 to 100 %.[31]. The validity of VTE 321 
discharge diagnoses in  DNPR was investigated by Severinsen et al. (2010) who found a positive 322 
predictive value of 75% for diagnoses coded at wards[32].  323 
Confounding by indication could arise if the indication for hysterectomy carries a risk of developing 324 
VTE. Most other studies included patients with both benign and malignant diseases[6,19]. We 325 
chose to exclude patients with malignant disease and also obstetric patients, as these conditions 326 
are recognized risk factors for VTE[33,34]. 327 
 328 
Conclusion:  329 
The risk of postoperative VTE in the first 30 days after hysterectomy is low (0.19 %). Laparoscopic 330 
and vaginal approach to hysterectomy significantly reduce the risk of VTE when compared to 331 
abdominal approach and adjusted for age and relevant risk factors. Our results indicate that 332 
postsurgical use of pharmacologic thromboprophylaxis reduce the risk of VTE. If heparin 333 
prophylaxis is not routinely used we suggest individual evaluation in each patient considering 334 
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approach to surgery, concomitant disease and previous thromboembolic events. 335 
 336 
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 428 
 429 
Figure 1. Flowchart presenting the patient selection using Danish National Registries. 430 
 431 
Figure 2. Multivariable Cox proportional Hazards Regression analysis presenting hazard ratios of 432 
venous thromboembolism associated with the approach to hysterectomy, adjusted for age, time 433 
period, ovarian and uterine neoplasm, use of sex hormones, a history of acute myocardial 434 
infarction (AMI) and previous venous thromboembolism (VTE). 435 
Abdominal hysterectomy is used as reference in the main exposure group, among categorical 436 
variables in the confounder group exposed individuals are compared to non-exposed. 437 
 438 
Figure 3. Multivariable Cox proportional Hazards Regression analysis presenting hazard ratios of 439 
venous thromboembolism associated with the approach to hysterectomy, adjusted for age, use of 440 
postoperative thromboprophylaxis, ovarian and uterine neoplasm, use of sex hormones and a 441 
history of acute myocardial infarction (AMI) and previous venous thromboembolism (VTE). 442 
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Stratified for period, showing results after 2003. Abdominal hysterectomy is used as reference in 443 
the main exposure group, among categorical variables in the confounder group exposed 444 
individuals are compared to non-exposed. 445 
 446 
Figure S1. Cumulative incidence of venous thromboembolism 30 days following hysterectomy. 447 
 448 
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Mean age, years 49.9 10.4 47.9 10.5 54.3 13.2 
50.7 
11.3 
Median length of stay, days 
(interquartile range)  3 (2,5)   1 (1,2)  2 (1,2)  3 (2,4)  
Length of stay data missing 4 1 10 15 
Body Mass Index (BMI) 26.25.2 25.75.3 25.94.7 26.15.0 
BMI missing 52,706 8,394 17,654 78,754 
Anticoagulant drugs 631 (1.1) 110 (1.2) 177 (0.8) 918 (1.0) 
Antiplatelet drugs  2,243 (3.8) 359 (3.9) 1,633 (7.6) 
4,235 
(4.7) 
Hormonal contraception  4,422 (7.5) 894 (9.7) 1,280 (6.0) 
6,596 
(7.3) 
Hormone therapy 7,183 (12.1) 927 (10.1) 4,821 (22.4) 
12,931 
(14.4) 
Hysterectomy before 2004  29,060 (49.1) 2,166 (23.5) 5,139 (23.9) 
36,363 
(40.4) 






Abnormal uterine bleeding 21,187 (35.8) 4,389 (47.7) 7,806 (36.3) 
33,382 
(37.1) 
Benign ovarian neoplasm 4,910 (8.3) 292 (3.2) 189 (0.9) 
5,391(6.0
) 
Uterine fibroids 34,849 (58.8) 3,314 (36.0) 4,888 (22.7) 
43,051 
(47.9) 
Pelvic organ prolapse 1,209 (2.0) 319 (3.5) 10,935 (50.9) 
12,463 
(13.9) 
Pelvic pain 8,536 (14.4) 2,061 (22.4) 3,115 (14.5) 
13,712 
(15.2) 
Endometriosis 5,161 (8.7) 1,192 (13.0) 1,191 (5.5) 
7,544 
(8.4) 
Cervical intraepithelial neoplasia 1,958 (3.3) 624 (6.8) 872 (4.1) 
3,454 
(3.8) 
Endometrial hyperplasia 485 (0.8) 123 (1.3) 184 (0.9) 792 (0.9) 
Urinary incontinence 628 (1.1) 66 (0.7) 588 (2.7) 
1,282 
(1.4) 
Cancer predisposition 100 (0.2) 91 (1.0) 8 (0.04) 199 (0.2) 
 
Concomitant diseases 
Ischemic heart disease 1,498 (2.5) 329 (3.6) 902 (4.2) 
2,729 
(3.0) 
Cardiovascular disease 873 (1.5) 176 (1.9) 419 (1.9) 
1,468 
(1.6) 
History of acute myocardial 
infarction 320 (0.5) 67 (0.7) 186 (0.9) 573 (0.6) 
Thrombophilia  266 (0.4) 68 (0.7) 120 (0.6) 454 (0.5) 
Varicose disease 1,838 (3.1) 350 (3.8) 1,166 (5.4) 
3,354 
(3.7) 
Heart failure 345 (0.6) 53 (0.6) 158 (0.7) 556 (0.6) 
Chronic obstructive lung disease 720 (1.2) 136 (1.5) 337 (1.6) 1,193 
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Previous VTE 1,026 (1.7) 182 (2.0) 332 (1.5) 
1,540 
(1.7) 
     
Postoperative VTE prophylaxis
‡  N=30,171 N=7,032 N=16,363 
N=53,56
6 
No prophylaxis 13,755 (45.6) 2,797 (39.8) 5,623 (34.4) 
22,175 
(41.4) 
VTE prophylaxis 16,416 (54.4) 4,235 (60.2) 10,740 (65.6) 
31,391 
(58.6) 
* Data are expressed as N (column %), mean  SD.  454 
†There could be more than one indication for hysterectomy. 455 
‡ Only registered in patients undergoing surgery after 2003. 456 
 457 
 458 
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Table 2. Unadjusted hazard ratios (HRs) of venous thromboembolism (VTE) in 459 
different exposure groups  460 
  VTE events/N 
total 
HR 95 % CI P value 
Age (by decade) 175/89,931 1.16 1.02-1.31 .019 
Age<60 years 129/72,847 1.0 (reference)   
Age60 years 46/17.084 1.53 1.09-2.14 .013 
Length of stay (LOS), days* 175/89,577 1.09 1.05-1.13 <.001 
Abdominal hysterectomy 142/59,231 1.0 (reference)   
Laparoscopic hysterectomy 12/9,198 0.54 0.30-0.98 .042 
Vaginal hysterectomy 21/21,502 0.41 0.26-0.64 <.001 
Previous VTE  67/1,540 36.7 27.1-49.8 <.001 
Previous acute myocardial infarction 6/573 5.7 2.5-12.8 <.001 
Benign ovarian neoplasm 11/5,391 1.05 0.57-1.94    .867 
Uterine fibroids 76/43,051 0.83 0.62-1.13 .834 
Abnormal uterine bleeding 55/33,318 0.78 0.56-1.07 .117 
Hormone therapy 24/12,931 0.95 0.62-1.46 .804 
Contraceptives 13/6,596 1.01 0.58-1.78 .965 
Anticoagulant drugs 31/918 21.5 14.6-31.7 <.001 
 
Surgery after 2003 
    
After implementation of VTE prophylaxis 105/53,566 1.02 0.75-1.38    .907 
VTE prophylaxis registered 43/31,391 0.49 0.33-0.72 <.001 
*354 patients with missing data on LOS or LOS exceeding follow-up time of 30 days were excluded from the   461 




  466 
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  471 
Women18 years of age undergoing 
hysterectomy in the period from January 
1996 until December 2015 
N = 109,280 
Hysterectomies with one month of follow-up  
N = 108,766 
Hysterectomies for benign disease  
N = 89,931 
Hysterectomies sorted by approach 
Abdominal hysterectomies (N = 59,231) 
Laparoscopic hysterectomies (N = 9,198) 
Vaginal hysterectomies (N = 21,502) 
Missing data on date of surgery (N = 310) 
One-month follow-up data not available due 
to surgery in December 2015 (N = 204) 
 
Excluded diagnoses (N = 17,784): 
Patients diagnosed with any type of cancer 
within one month prior to or two months 
after hysterectomy (DC00-DC96) 
Radical hysterectomies (N = 1,051) 
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